OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc.
Metrics to compare | OPTN | Peers Peers - average of corresponding metrics from companies closely matching OPTN: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOPTNPeersSector |
---|---|---|---|---|
P/E Ratio | −3.3x | 0.0x | −0.5x | |
PEG Ratio | −0.09 | 0.00 | 0.00 | |
Price/Book | −1.6x | 0.0x | 2.6x | |
Price / LTM Sales | 1.2x | 0.0x | 3.3x | |
Upside (Analyst Target) | −6.3% | 0.0% | 43.4% | |
Fair Value Upside | Unlock | 0.0% | 7.1% | Unlock |